UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer

Clinical cancer research, 2013-03, Vol.19 (5), p.1213-1224

2013

Volltextzugriff (PDF)

Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer

Clinical cancer research, 2014-12, Vol.20 (23), p.6163-6174

2014

Volltextzugriff (PDF)

Characterization of latently infected EBV+ antibody-secreting B cells isolated from ovarian tumors and malignant ascites

Frontiers in immunology, 2024-07, Vol.15, p.1379175

2024

Volltextzugriff (PDF)

Intestinal Radiation Protection and Mitigation by Second-Generation Probiotic Lactobacillus-reuteri Engineered to Deliver Interleukin-22

International journal of molecular sciences, 2022-05, Vol.23 (10), p.5616

2022

Volltextzugriff (PDF)

Immunotherapy Advances for Epithelial Ovarian Cancer

Cancers, 2020-12, Vol.12 (12), p.3733

2020

Volltextzugriff (PDF)

Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression

Oncoimmunology, 2023-12, Vol.12 (1), p.2198185-2198185

2023

Volltextzugriff (PDF)

Longitudinal Modulation of Loco-Regional Immunity in Ovarian Cancer Patients Receiving Intraperitoneal Chemotherapy

Cancers, 2022-11, Vol.14 (22), p.5647

2022

Volltextzugriff (PDF)

Genetically Engineered Probiotic Limosilactobacillus reuteri Releasing IL-22 (LR-IL-22) Modifies the Tumor Microenvironment, Enabling Irradiation in Ovarian Cancer

Cancers, 2024-01, Vol.16 (3), p.474

2024

Volltextzugriff (PDF)

MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location

PloS one, 2014-07, Vol.9 (7), p.e102409-e102409

2014

Volltextzugriff (PDF)

Release of Interferon-β (IFN-β) from Probiotic Limosilactobacillus reuteri -IFN-β (LR-IFN-β) Mitigates Gastrointestinal Acute Radiation Syndrome (GI-ARS) following Whole Abdominal Irradiation

Cancers, 2023-03, Vol.15 (6), p.1670

2023

Volltextzugriff (PDF)

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade

Oncogene, 2019-01, Vol.38 (3), p.390-405

2019

Volltextzugriff (PDF)

Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles

Oncogene, 2019-03, Vol.38 (13), p.2380-2393

2019

Volltextzugriff (PDF)

Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model

Molecular pharmaceutics, 2015-02, Vol.12 (2), p.542-553

2015

Volltextzugriff (PDF)

MUC1 Immunobiology: From Discovery to Clinical Applications

Advances in Immunology, 2004, Vol.82, p.249-293

2004

Volltextzugriff (PDF)

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies

Cancer management and research, 2011, Vol.3 (default), p.25-38

2011

Volltextzugriff (PDF)

Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity

Clinical cancer research, 2022-05, Vol.28 (10), p.2038-2049

2022

Volltextzugriff (PDF)

A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells

Disease models & mechanisms, 2009-11, Vol.2 (11-12), p.593-603

2009

Volltextzugriff (PDF)

Lactobacillus reuteri Releasing IL-22 (LR-IL-22) Facilitates Intestinal Radioprotection for Whole-Abdomen Irradiation (WAI) of Ovarian Cancer

Radiation research, 2022-07, Vol.198 (1), p.89

2022

Volltextzugriff (PDF)

The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells

The Journal of immunology (1950), 2000-10, Vol.165 (7), p.3730-3741

2000

Volltextzugriff (PDF)

Chronic inflammation in endometriosis and endometriosis-associated ovarian cancer: New roles for the "old" complement pathway

Oncoimmunology, 2015-05, Vol.4 (5), p.e1002732

2015

Volltextzugriff (PDF)

Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition

Science advances, 2021-11, Vol.7 (46), p.eabi5790-eabi5790

2021

Volltextzugriff (PDF)

Plasma microRNAs in ovarian cancer--response

Clinical cancer research, 2013-06, Vol.19 (12), p.3326-3326

2013

Volltextzugriff (PDF)

Summary of the 2016 American Association for Cancer Research (AACR) Annual Meeting

Gynecologic oncology, 2016-07, Vol.142 (1), p.9-12

2016

Volltextzugriff (PDF)

Abstract 3208: Chemo-induced biology of PD-L1 and in vivo combination immune therapy for ovarian cancer

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3208-3208

2016

Volltextzugriff (PDF)

Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice

Biological chemistry, 2009-07, Vol.390 (7), p.611-618

2009

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(54)

Sprache

Englisch
(54)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer

Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer

Characterization of latently infected EBV+ antibody-secreting B cells isolated from ovarian tumors and malignant ascites

Intestinal Radiation Protection and Mitigation by Second-Generation Probiotic Lactobacillus-reuteri Engineered to Deliver Interleukin-22

Immunotherapy Advances for Epithelial Ovarian Cancer

Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression

Longitudinal Modulation of Loco-Regional Immunity in Ovarian Cancer Patients Receiving Intraperitoneal Chemotherapy

Genetically Engineered Probiotic Limosilactobacillus reuteri Releasing IL-22 (LR-IL-22) Modifies the Tumor Microenvironment, Enabling Irradiation in Ovarian Cancer

MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location

Release of Interferon-β (IFN-β) from Probiotic Limosilactobacillus reuteri -IFN-β (LR-IFN-β) Mitigates Gastrointestinal Acute Radiation Syndrome (GI-ARS) following Whole Abdominal Irradiation

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade

Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles

Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model

MUC1 Immunobiology: From Discovery to Clinical Applications

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies

Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity

A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells

Lactobacillus reuteri Releasing IL-22 (LR-IL-22) Facilitates Intestinal Radioprotection for Whole-Abdomen Irradiation (WAI) of Ovarian Cancer

The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells

Chronic inflammation in endometriosis and endometriosis-associated ovarian cancer: New roles for the "old" complement pathway

Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition

Plasma microRNAs in ovarian cancer--response

Summary of the 2016 American Association for Cancer Research (AACR) Annual Meeting

Abstract 3208: Chemo-induced biology of PD-L1 and in vivo combination immune therapy for ovarian cancer

Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice

Aktive Filter

Suchergebnisse filtern